Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves ZELSUVMIâ„¢ as First-in-Class Treatment for Molluscum Contagiosum
Details : Zelsuvmi (berdazimer topical gel, 10.3%) is a nitric oxide (NO) releasing agent which is approved for the topical treatment of molluscum contagiosum in adults and pediatric patients one year or older.
Product Name : Zelsuvmi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 21-Valent Pneumococcal Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : V116 is an investigational, 21-valent pneumococcal conjugate vaccine in Phase 3 development for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in the adult population.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 27, 2023
Lead Product(s) : 21-Valent Pneumococcal Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Novan
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SB206 (berdazimer sodium), the active ingredient in berdazimer gel, 10.3% (SB206), is a new chemical entity, for the treatment of molluscum contagiosum is a potential first-in-class topical nitric oxide-releasing agent with positive Phase 3 data submitte...
Product Name : Zelsuvmi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2023
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Novan
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Approval from China’s NMPA for sugemalimab (Cejemly®), an OmniAb-derived anti-PD-L1 monoclonal antibody, for the first-line treatment of metastatic NSCLC in combination with chemotherapy is based on the Phase 3 study.
Product Name : Cejemly
Product Type : Antibody
Upfront Cash : Inapplicable
December 22, 2021
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : GSK
Deal Size : $257.5 million
Deal Type : Collaboration
Ligand and GSK Expand Global Collaboration and License Agreement
Details : This new agreement builds upon the initial December 2020 agreement to identify and develop inhibitors of a specific genetically-validated molecular target relevant to neurological diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $10.0 million
December 21, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : GSK
Deal Size : $257.5 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CR Double-Crane Pharmaceuticals Co., Ltd
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Ligand has preclinical data showing its oral BEPro-enabled COVID-19 antivirals to have a favorable blood concentration profile and generate lower levels of active nucleotide in the kidney, a potential site for toxicity, than other oral and intravenous co...
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
October 21, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CR Double-Crane Pharmaceuticals Co., Ltd
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Asparaginase Erwinia Chrysanthemi (Recombinant)
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Jazz Pharmaceuticals
Deal Size : $162.5 million
Deal Type : Partnership
Details : Rylaze is a recombinant erwinia asparaginase used as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients 1 month or older with hypersensitivity to E. coli-derive...
Product Name : Rylaze
Product Type : Enzyme
Upfront Cash : Undisclosed
July 21, 2021
Lead Product(s) : Asparaginase Erwinia Chrysanthemi (Recombinant)
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Jazz Pharmaceuticals
Deal Size : $162.5 million
Deal Type : Partnership
Lead Product(s) : Pneumococcal 15-Valent Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Merck & Co
Deal Size : $2.0 million
Deal Type : Licensing Agreement
Details : VAXNEUVANCE is a 15-valent pneumococcal vaccine utilizing Ligand’s CRM197 vaccine carrier protein, which is produced using the patent-protected Pelican Expression Technology™ platform.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 19, 2021
Lead Product(s) : Pneumococcal 15-Valent Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Merck & Co
Deal Size : $2.0 million
Deal Type : Licensing Agreement
Lead Product(s) : 15-Valent Pneumococcal Conjugate Vaccine,CRM197
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : $1.5 million
Deal Type : Collaboration
Ligand Receives Milestone Payment from Merck
Details : Milestone payment triggered by acceptance for review of a BLA for V114, an investigational 15-valent pneumococcal conjugate vaccine that utilizes Ligand’s CRM197 carrier protein.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 13, 2021
Lead Product(s) : 15-Valent Pneumococcal Conjugate Vaccine,CRM197
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : $1.5 million
Deal Type : Collaboration
Details : The deal will leverage Icagen’s expertise in small molecule therapeutics targeting transmembrane proteins, utilising the company’s discovery technology to identify and develop inhibitors of a ‘specific genetically-validated molecular target’ rele...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $7.0 million
December 21, 2020